Researchers Announce Pancreatic Cancer Pill Shrank Tumors in 60% of Patients

Medical researchers announced on Friday, Nov. 20, 2026, that a daily pill called daraxonrasib successfully shrank or stopped the growth of tumours in advanced pancreatic cancer patients during early trials.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The trial evaluated 61 patients who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. During the study, tumours stopped growing in 90% of the participants. Just over 60% of patients experienced shrinkage or disappearance of their tumours, and for roughly 8% of the group, the cancer became undetectable on CT scans.

Michelle Mitchell, the chief executive of Cancer Research UK, described the treatment as “the biggest leap forward we’ve seen in decades for pancreatic cancer patients.”

The charity said that more than 11,000 people are diagnosed with pancreatic cancer in the UK each year, while more than 10,000 die from the disease. Pancreatic cancer carries the lowest survival rate among all common cancers in the UK and shares a similarly poor prognosis globally.

Daraxonrasib works as a KRAS inhibitor by locking onto and shutting off specific mutations that drive tumour growth in most pancreatic cancers.

The protein targeted by the drug is nicknamed the “Death Star” because it has historically proven exceptionally difficult to attack with medications. Previous findings indicated that the pill doubled average life expectancy for patients whose cancer had spread and who had already received standard treatment, with median survival reaching 13.2 months compared to 6.7 months for chemotherapy alone.

Tumours Stopped Growing in 90% of Patients

Trial Outcomes for Daraxonrasib and Chemotherapy Combination
Clinical Outcome Patient Percentage
Tumours stopped growing 90%
Tumours shrank or disappeared Over 60%
Cancer undetectable on CT scans About 8%
Patients alive one year after starting treatment 76.6%

Patients in the trial were followed for a median of 18.3 months, with some individuals showing no return of the cancer during this period. One year after starting treatment, 76.6% of patients were alive. By comparison, chemotherapy alone typically yields a one-year survival rate of 40% to 45%.

“This is the closest to cure,” Park said, adding that he had never previously seen so many tumours disappear in patients with spreading cancer. Researchers emphasized that the pill cannot yet be considered a cure. Doctors do not yet know how long the medication can keep the disease at bay, and longer studies are required to determine whether any of the cancers can be put into permanent remission.

Researchers Test Treatment in Global Phase III Trial

Because KRAS gene mutations also drive dozens of other malignancies, including lung and ovarian cancers, researchers hold hope that the treatment could eventually benefit patients with other types of tumors. Dr Sam Godfrey of Cancer Research UK told BBC News that the results show progress that is long overdue for a notoriously difficult disease.

“What this new drug has done is it’s found a way of drugging the undruggable,” Godfrey said.

To confirm whether these early findings translate into improved outcomes on a larger scale, researchers are conducting the global Phase III RASolute-303 trial, which is being led by Park. This larger study evaluates daraxonrasib as both a standalone treatment and in combination with gemcitabine and nab-paclitaxel, comparing those regimens against chemotherapy alone.

Memorial Sloan Kettering Cancer Center traces its origins to the 1884 founding of New York Cancer Hospital, the nation’s first dedicated cancer hospital, by a group that included John Jacob Astor III.

In 1945, Alfred P. Sloan and Charles F. Kettering of General Motors established the adjacent Sloan-Kettering Institute for Cancer Research, applying industrial laboratory methods to oncology. The two entities formally coordinated operations in 1960 and merged in 1980, creating one of the original National Cancer Institute–designated Comprehensive Cancer Centers.

Common Questions About Pancreatic Cancer Symptoms and Treatment

* What are the common early symptoms of pancreatic cancer?
The NHS and Pancreatic Cancer UK list symptoms including persistent indigestion or bloating, pain in the upper tummy or back that may worsen after eating, unexplained weight loss, and loss of appetite. Experts advise getting persistent digestive changes checked by a general practitioner if they do not settle within two weeks.

* How does daraxonrasib target cancer cells?

Daraxonrasib is a KRAS inhibitor designed to bind to the RAS protein and block signals that pancreatic cancer cells depend on for survival and growth. Revolution Medicines said that the Phase 1/2 RMC-GI-102 open-label study evaluated the drug in combination with gemcitabine and nab-paclitaxel.

* Is daraxonrasib available on the National Health Service?

The treatment is not yet available for general use on the NHS. Cancer Research UK said that further clinical trials are necessary before the therapy can be formally assessed for routine clinical prescription.